Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies

Activating NRAS mutations are found in 15-20% of melanomas. Immune therapies have become a mainstay in advanced melanoma treatment. We sought to evaluate whether tumor genotype (e.g. NRAS mutations) correlate with benefit from immune therapy in melanoma. We identified 229 melanoma patients treated w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Immunol Res
Autors principals: Johnson, Douglas B., Lovly, Christine M., Flavin, Marisa, Panageas, Katherine S., Ayers, Gregory D., Zhao, Zhiguo, Iams, Wade T., Colgan, Marta, DeNoble, Sarah, Terry, Charles R., Berry, Elizabeth G., Iafrate, A. John, Sullivan, Ryan J., Carvajal, Richard D., Sosman, Jeffrey A.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4351797/
https://ncbi.nlm.nih.gov/pubmed/25736262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-14-0207
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars